CD47 levels were found to be higher in LUAD tissues following treatment with sorafenib compared to tumor tissues prior to treatment, consistent with a report that CD47 was upregulated in liver cancers resistant to sorafenib [130,157]. This evidence concerns the gene CD47 and neoplasm.